Hyundai Hope on Wheels contributes $250,000 to support the art therapy program at the Charles-Bruneau Foundation for children ...

Pancreatic cancer is one of the deadliest diseases known to medicine. It’s hard to detect, quick to spread, and resistant to most treatments. With a five-year survival rate of just 13%, pancreatic ...

The trial of a new drug, bexobrutideg, shows promising results for chronic lymphocytic leukemia patients previously treated ...

Baystreet.ca News Commentary – Cancer drug prices are rising sharply, with Bloomberg reporting growing concern over ...

Researchers sought to determine whether a reduced dose of apixaban would be as effective as using full-dose apixaban in preventing recurrent VTE in patients with active cancer.

Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

While research in mice has shown encouraging results, the next phases of human trials will need to confirm safety and ...

Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved ...

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...